CRISPR screening tool exposes new leukaemia drug target
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
List view / Grid view
News
Antidepressants inhibit growth of pancreatic and colon cancers in mice
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
NINDS awards Sinopia $3.3m for development of Parkinson’s drug candidate
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
Scientists uncover mechanisms of potential COVID-19 drug targets
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.
CRISPR-based droplet method speeds up gene therapy research
The new CRISPR-based technology called MIC-Drop rapidly identified several genes for heart development and function in zebrafish.
“Ultrasensitive” HPV detection paves way for precision treatment
A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.
Promising pre-clinical data announced for Parkinson’s drug
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
New AI technology could shape the future of RNA therapeutics
Artificial intelligence was shown to predict the 3D shapes of RNA molecules, which could significantly advance RNA therapeutics.
Ground-breaking small molecule attenuates neuroinflammation in mice
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
New AI method could aid in development of T cell-based cancer therapies
An artificial intelligence technique can identify which neoantigens are recognised by the immune system, possibly improving cancer prognosis and treatment.
Sanofi acquires Translate Bio for mRNA therapeutic development
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
Mechanism discovery provides new model for studying multiple sclerosis
The over-expression of a growth factor receptor resulted in hypomyelination, leading to diseases such as multiple sclerosis in mouse models.
Lymph node-targeted vaccine elicits COVID-19 protection in vivo
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
Exosome-based approach reduces levels of HIV in mice
Scientists have used exosomes to deliver a novel protein that prevented HIV from replicating in the bone marrow, spleen and brain of mouse models.
Scientists uncover key that permits hepatitis C entry into cells
A new study has identified a key protein on the surface of the hepatitis C virus that interacts with a receptor found on human cells.